Glenmark Pharma Arm Signed Pact with Beigene to Deliver Oncology Medicines in India. 

Glenmark Pharma said its subsidiary Glenmark Speciality S.A. has signed an exclusive marketing and distribution arrangement of Tislelizumab and Zanubrutinib with BeiGene, a global oncology company.

Tislelizumab, a novel anti-PD-1 monoclonal antibody approved by NMPA, EMA and FDA for treating advanced or metastatic esophageal squamous cell carcinoma and broad development for treating various types of cancers. 

Company Details

Zanubrutinib is a BTK inhibitor approved to treat hematological malignancies, with the results of several studies reinforcing its favorable efficacy and safety profile.

Under this collaboration, Glenmark will be responsible for locally required development, registration and distribution, providing access to BeiGene's innovative oncology medicines for cancer patients across India. 

This partnership is important as many low-and middle-income countries, including India, are experiencing an increasing cancer burden.

Open Demat A/C